Patents Issued in July 4, 2024
-
Publication number: 20240216523Abstract: The present invention relates to compositions and methods for effective delivery of an agent to a stem cell using a delivery vehicle comprising a stem cell targeting domain.Type: ApplicationFiled: April 29, 2022Publication date: July 4, 2024Inventors: Hamideh Parhiz, Drew Weissman
-
Publication number: 20240216524Abstract: Novel biomolecular conjugates containing non-natural aromatic chemical moieties covalently coupled to a diazonium compound and methods of their use are disclosed.Type: ApplicationFiled: December 14, 2023Publication date: July 4, 2024Inventors: Abhishek Chatterjee, Partha Sarathi Addy
-
ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES
Publication number: 20240216525Abstract: Enzyme-triggered self-reacting arm compounds and chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. A Ligand-Drug-Conjugate (LDC) includes such enzyme-triggered self-reacting arms.Type: ApplicationFiled: March 30, 2022Publication date: July 4, 2024Applicants: MABLINK BIOSCIENCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Warren VIRICEL, Benoît JOSEPH, Guy FOURNET -
Publication number: 20240216526Abstract: Provided are a dual-drug link assembly unit represented by formula III, or a stereoisomer thereof, or an optical isomer thereof. The dual-drug link assembly unit can be linked to a targeting linker to obtain a dual-drug targeting linker-drug conjugate represented by formula I. The specific structure can effectively reduce the aggregation of the dual-drug targeting linker-drug conjugate, which facilitates process scale-up, thereby improving the efficiency of the targeting effect on tumor cells, reducing the toxic and side effects on normal cells, and at the same time, effectively overcoming drug resistance and achieving a synergistic anti-tumor effect. Compared with DS-8201 which is already on the market, the ADC provided by the present invention significantly improves the inhibition effect on HER2 positive cell strains N87 and SK—BR-3d.Type: ApplicationFiled: March 15, 2022Publication date: July 4, 2024Inventors: Jinkun HUANG, Jiahao GENG, Chaoyang FENG, Junqiang LIU, Yue LU, Lei LI, Chenglong WU, Fang CHEN, Dejian XIE
-
Publication number: 20240216527Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.Type: ApplicationFiled: March 14, 2024Publication date: July 4, 2024Applicants: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Serv.Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
-
Publication number: 20240216528Abstract: An antitumor chemotherapeutic drug liposome having a low drug-to-lipid ratio and an application thereof. The antitumor chemotherapeutic drug liposome comprises an antitumor drug and a liposome as a carrier, wherein the drug-to-lipid ratio of the antitumor drug to the lipid carrier is between 0.01 and 0.15.Type: ApplicationFiled: May 20, 2022Publication date: July 4, 2024Applicant: Highfield Biopharmaceuticals CorporationInventors: Yuhong Xu, Xiaolong Chen, Shanshan Jin
-
Publication number: 20240216529Abstract: The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a targeting moiety and a biologically active molecule via an optional linker, which may be useful as an agent for the prophylaxis or treatment of diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.Type: ApplicationFiled: December 22, 2022Publication date: July 4, 2024Applicant: BIORCHESTRA CO., LTD.Inventor: Jin-Hyeob RYU
-
Publication number: 20240216530Abstract: Compositions and methods are provided for treating myopathies by administering a complex formed between a therapeutic mRNA polynucleotide and a 3E10 antibody or variant thereof, or antigen-binding fragment thereof. In some instances, the complexes are stabilized through a molar ratio of 3E10 antibody or variant thereof, or antigen-binding fragment thereof to therapeutic polynucleotide of at least about 2:1.Type: ApplicationFiled: March 3, 2022Publication date: July 4, 2024Inventors: Elias Quijano, Peter Glazer, Bruce C. Turner, Stephen Squinto
-
Publication number: 20240216531Abstract: Disclosed is a chitosan-containing vector as set forth in formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined herein, and w, p, and z are integers varying from 0 to 1500, the sum of which is between 50 and 1500, so as to define a chitosan backbone with a molecular weight between 10 kDa and 300 kDa. The chitosan-containing vector comprising 5% to 55% of N,N-diisopropylethylamine, relatively to the sum of w, p, and z, and up 5% for pegylated units. There is also described the use of this vector with a siRNA as a mean for transfection or transformation of the siRNA for treating various diseases.Type: ApplicationFiled: March 25, 2022Publication date: July 4, 2024Inventors: Marcio José TIERA, Julio Cesar FERNANDES, André Miguel MARTINEZ JUNIOR, Ricchard Hallan Felix VIEGAS DE SOUZA, Mohamed BENDERDOUR, Francis VALLIERES
-
Publication number: 20240216532Abstract: Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for treating Fanconi anemia (FA).Type: ApplicationFiled: April 26, 2022Publication date: July 4, 2024Inventors: Jonathan THON, David RAISER, Laura GOLDBERG
-
Publication number: 20240216533Abstract: Provided are a new herpes simplex virus type I, a genetically modified herpes simplex virus, a composition containing the virus, a host cell and a cell culture, and the use of the virus in the treatment of diseases.Type: ApplicationFiled: March 4, 2021Publication date: July 4, 2024Inventors: Jingshu ZHAO, Xiaopeng LI, Chao TIAN, Hua ZHOU, Tiantian WANG
-
Publication number: 20240216534Abstract: Aspects of the disclosure relate to compositions and methods for gene editing in a cell or subject. In some aspect, the present disclosure provides an isolated nucleic acid comprising an expression construct comprising transgene encoding a gene product flanked by a 5? homology arm and a 3? homology arm, wherein the expression construct is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).Type: ApplicationFiled: April 26, 2022Publication date: July 4, 2024Applicant: University of MassachusettsInventors: Terence Flotte, Allison Keeler-Klunk
-
Publication number: 20240216535Abstract: The application describes methods and compositions comprising ceDNA vectors useful for the expression of anti-CoV-2 S antibodies and antigen-binding fragments thereof in a cell, tissue or subject, and methods of treatment of COVID-19 with said ceDNA vectors.Type: ApplicationFiled: April 27, 2022Publication date: July 4, 2024Inventors: Nathaniel Silver, Fabio Benigni
-
Publication number: 20240216536Abstract: A novel vector, composition and method of treating a UBE3A deficiency disease is presented. A novel UBE3A vector construct was generated with an additional secretion sequence to allow the secretion from cells. This secreted only E6AP protein maintains its presence outside the cell and is capable of diffusing to greater distances to cover more of the brain and rescue disease pathology.Type: ApplicationFiled: December 21, 2023Publication date: July 4, 2024Inventor: Kevin Ron Nash
-
Publication number: 20240216537Abstract: Provided herein, inter alia, are methods and compounds for treating and preventing neural cell death, e.g., retinal ganglion cell death. Also provided herein, inter alia, are methods and compounds for treating and preventing nerve degeneration. The methods and compounds provided herein may treat or prevent glaucoma.Type: ApplicationFiled: April 11, 2022Publication date: July 4, 2024Inventors: Derek S. WELSBIE, Mai T. VU, Cassidy D. LEE, Amit K. PATEL
-
Publication number: 20240216538Abstract: Complement activation occurs via three main pathways: the antibody-dependent classical pathway, the alternative pathway, and the mannose-binding lectin (MBL) pathway. Inappropriate or excessive complement activation is an underlying cause or contributing factor to a number of serious diseases and conditions, and considerable effort has been devoted over the past several decades to exploring various complement inhibitors as therapeutic agents. Methods, systems, and compositions for genomic editing of a gene encoding a complement protein, e.g., C3, are disclosed.Type: ApplicationFiled: May 26, 2022Publication date: July 4, 2024Inventor: Lukas Scheibler
-
Publication number: 20240216539Abstract: The present application relates to a vector for delivering an active agent to the nervous system. In one embodiment of the present application, a vector for delivering an active agent in which one or more TTR ligands are conjugated to the surface of an adeno-associated virus is provided.Type: ApplicationFiled: February 28, 2024Publication date: July 4, 2024Inventors: Jae Young Lee, Sang Woo Ham, Hee Sook Bae, Gyu Bon Cho, Jae Hyung Jang, Yun Ha Kim, Dong Soo Lee
-
Publication number: 20240216540Abstract: The disclosure provides compositions containing polynucleotides that encode a stereocilin protein under regulatory control of an outer hair cell-specific promoter, as well as two-vector systems containing the same, that can be used to promote expression of stereocilin specifically in outer hair cells. Additionally, the compositions described herein may be used for the treatment of subjects having or at risk ofdeveloping hearing loss, such as hearing loss associated with a mutation in stereocilin.Type: ApplicationFiled: May 5, 2022Publication date: July 4, 2024Inventors: Joseph BURNS, Martin SCHWANDER, XuDong WU, Lars BECKER, Tyler GIBSON, Ning PAN
-
Publication number: 20240216541Abstract: Compositions and methods for preventing and treating cardiac arrhythmia. Methods of preventing or treating arrhythmogenic right ventricular cardiomyopathy (ARVC), comprising administering to a subject in need a prophylactic or treatment effective amount of a composition comprising a plakophilin-2 (PKP2) gene. The composition further comprises an adenovirus-associated vector (AAV) to deliver the PKP-2 gene. In embodiments, the invention provides that the AAV is a cardiotropic AAV serotype and contains a cardiac-specific promoter. Method of treating a cardiovascular disease characterized by abnormal cardiac cell-cell junction complex comprising administering to a subject in need a prophylactic or treatment effective amount of a composition comprising a plakophilin-2 (PKP2) gene.Type: ApplicationFiled: April 12, 2022Publication date: July 4, 2024Inventors: Farah Sheikh, William Bradford
-
Publication number: 20240216542Abstract: Aspects of the disclosure relate to methods for expressing one or more Ganglioside GM3 synthase (GM3S) isoforms in a cell or subject. In some aspects, the disclosure relates to methods for treating GM3 synthase deficiency in a subject in need thereof by administering an rAAV expressing one or more Ganglioside GM3 synthase (GM3S) isoforms via intracerebroventricular (ICV) administration.Type: ApplicationFiled: April 18, 2022Publication date: July 4, 2024Applicants: University of Massachusetts, The Clinic for Special Children, Inc.Inventors: Huiya Yang, Guangping Gao, Kevin A. Strauss, Dan Wang
-
Publication number: 20240216543Abstract: Provided are methods of treating or ameliorating the symptoms of dystrophinopathies, such as Duchenne muscular dystrophy and Becker muscular dystrophy by administration of therapeutically effective doses of recombinant adeno-associated viruses (rAAV) containing a transgene encoding a microdystrophin.Type: ApplicationFiled: April 26, 2022Publication date: July 4, 2024Inventors: Olivier Danos, SunJung Kim, Nicholas Buss, Ye Liu, Chunping Qiao, Michele Fiscella, Hiren Patel
-
Publication number: 20240216544Abstract: Provided herein are compositions and systems for reconstitution of RNA molecules, including methods for using these molecules. For example, such molecules can be used to deliver a protein coding sequence over two or more viral vectors (such as AAVs), resulting in reconstitution of the full-length protein in a cell. Such methods can be used to deliver a protein involved in editing a nucleic acid molecule, for example to treat a genetic disease or cancer.Type: ApplicationFiled: May 16, 2022Publication date: July 4, 2024Applicant: Salk Institute for Biological StudiesInventors: Lukas Christoph Bachmann, Samuel Lawrence Pfaff
-
Publication number: 20240216545Abstract: The present disclosure provides, among other things, polynucleotide constructs, compositions, and methods of treating a disease or disorder, including administering to a subject in need thereof a composition comprising a polynucleotide construct comprising a 5? UTR, a mRNA encoding a protein of interest, and a 3? UTR.Type: ApplicationFiled: April 28, 2022Publication date: July 4, 2024Inventors: Owen DALY, James HEYES, Kieu LAM
-
Publication number: 20240216546Abstract: The present invention provides for model optimized drugs or combinations of drugs for the treatment of cancers associated with expression at least one human mutant KRAS protein variant, for example oncogenic G12KRAS human variants G12A, G12C, G12D, and G12V. The drugs or combinations of drugs are optimized by using genetically modified Drosophila that express the human mutant KRAS protein variant or an ortholog thereof that promotes tumorigenesis in the Drosophila, and evaluating whether the drug or combination of drugs results in the inhibition of tumorigenesis in the Drosophila.Type: ApplicationFiled: May 3, 2022Publication date: July 4, 2024Inventors: Santiago Nahuel Villegas, Annick Sawala, Deisy Guiretti, Cristina De Meguel Vijandi, Laura Towart
-
Publication number: 20240216547Abstract: The invention relates to fluorescein derivative compounds and the use thereof as fluorescent markers. Said markers can be used in particular in biology and in medicine, particularly in the field of ophthalmology. The non-fluorescent fluorescein derivatives are activated in the cell, thereby allowing the detection of living cells as well as the quantification of cell viability by fluorescence, without being toxic to cells.Type: ApplicationFiled: April 28, 2022Publication date: July 4, 2024Inventors: Philippe GAIN, Gilles THURET, Emilie COURRIER, Zhiguo HE, Gilles ULRICH, Antoinette DE NICOLA, Corantin MAURIN, Corentin MARET
-
Publication number: 20240216548Abstract: The method for preparing theragnostic carbon quantum dot nanomedicine composition comprises collecting and processing fresh plant samples of Azadirachta indica; mixing 50 g of crushed dried neem leaves powder with 500 mL of methanol and left to extract for 1 week; filtering the mixture and condensing using a rotary evaporator, and lyophilizing to obtain the extract; dissolving 0.57 g L-cysteine in 10 mL of deionized water and mixing with 1.5 g of citric acid to form a solution; ultrasonicating the solution for 10 minutes and then heating in a microwave oven for 4 minutes; cooling the solution to room temperature and then dissolving in 10 mL of deionized water to obtain a brown solution; centrifuging the brown solution at 9000 rpm for 10 minutes to remove impurities and filtering with a filter; and extracting the Carbon quantum dot (CQD) solution with ethyl acetate and storing in a refrigerator at 4° C.Type: ApplicationFiled: January 29, 2024Publication date: July 4, 2024Inventors: Madeeha Shehzad Lodhi, Muhammad Tahir Khan, Shabbir Muhammad, H. Algarni, Tayyaba Yasin, Dong Qing Wei, Sharifah Mohammed Ali Al-Moayid
-
Publication number: 20240216549Abstract: The present invention relates to ultrasound mediated enhancement of immunotherapeutic medicinal agents and regimens, and particularly for immunotherapeutic treatment of cancers and autoimmune diseases. More particularly, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery of immunotherapeutic agents to a targeted region of interest in the body and in enhancement of activated immune cell infiltration to targeted pathological conditions, and for treatment of solid tumours and autoimmune pathologies.Type: ApplicationFiled: April 20, 2022Publication date: July 4, 2024Inventors: Per Christian SONTUM, Svein KVÅLE, Spiros KOTOPOULIS, Andrew John HEALEY
-
Publication number: 20240216550Abstract: The present invention relates to a combination comprising a neurotensin receptor binding compound and NAPOLI for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.Type: ApplicationFiled: December 15, 2023Publication date: July 4, 2024Inventors: Stephan Klinz, Diane-Charlotte Imbs, Elodie Lewkowicz, Sylvie Rolland, Thomas Rohban, John R. Forbes
-
Publication number: 20240216551Abstract: This invention relates to new fibroblast activation protein (iFAP) inhibitory radiopharmaceuticals based on the molecule ((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl)pyrrolidin-2-yl)boronic acid (HYNIC-iFAP), where the hydrazine nitrogens of HYNIC act as favorable chemical groups for the interaction of the HYNIC-iFAP molecule with phenylalanine (Phe-350 and Phe-351), glutamic acid (Glu-203 and Glu-204) and with serine (Ser-624) in the active center of fibroblast activation protein (FAP), coupled with the conventional use of HYNIC as a chelating agent for the radiometal 99mTc, where ethylenediamine diacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The new radiopharmaceutical from 99mTc-EDDA/HYNIC-iFAP (99mTc-HYNIC-iFAP) detects, with high affinity in vivo, FAP expressed in the microenvironment of malignant tumors of epithelial origin using nuclear medicine SPECT molecular imaging techniques.Type: ApplicationFiled: October 14, 2021Publication date: July 4, 2024Applicant: INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARESInventors: Guillermina FERRO-FLORES, Blanca Elí OCAMPO-GARCÍA, Myrna Alejandra LUNA-GUTIÉRREZ, Clara Leticia SANTOS-CUEVAS, Nallely Patricia JIMÉNEZ-MANCILLA, Erika Patricia AZORIN-VEGA
-
Publication number: 20240216552Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.Type: ApplicationFiled: March 19, 2024Publication date: July 4, 2024Applicant: Vector Vitale IP LLCInventors: Peter NOVAK, Max TEMNIK, Oleksandr BALAKIN
-
Publication number: 20240216553Abstract: Among the various aspects of the present disclosure is the provision of compositions of CD163 targeting and theranostic agents and methods for use in detecting, monitoring, and evaluating CD163 associated diseases, disorders, and conditions.Type: ApplicationFiled: December 29, 2023Publication date: July 4, 2024Inventors: Yongjian Liu, Xiuli Zhang, Gyu Seong Heo
-
Publication number: 20240216554Abstract: Provided are compositions and methods for treating a solid or hematological cancer in a subject by administering an effective amount of a radioconjugated agent that targets one or more natural killer group 2, member D (NKG2D) ligands, alone or in combination with additional therapeutic agents or modalities. The radioconjugated NKG2DL-targeting agent targets NKG2DL-positive cells, such as tumor cells, depleting those cells and bystander NKG2DL-negative cells to effect overall tumor reduction. Moreover, radiation from the radioconjugated NKG2DL-targeting agent may increase expression of the target NKG2DL, leading to a feed-forward mechanism that further enhances the accumulation of the NKG2DL-targeting agent within the tumor.Type: ApplicationFiled: May 3, 2022Publication date: July 4, 2024Applicant: ACTINIUM PHARMACEUTICALS, INC.Inventors: Dale L Ludwig, Eileen GEOGHEGAN, Sandesh SETH, Jesse HWANG, Paul DIAMOND
-
Publication number: 20240216555Abstract: Methods for treating cancer are provided and include administering a radiolabeled 78-kDa glucose-regulated-protein (GRP78) binding agent (GRP78-binding agent) to a subject in need thereof. Methods for inhibiting prostate cancer growth in a subject and compositions which make use of a radiolabeled GRP78-binding agent are also provided.Type: ApplicationFiled: December 19, 2023Publication date: July 4, 2024Inventor: Vivek M. Rangnekar
-
Publication number: 20240216556Abstract: Provided herein are amyloid-reactive peptide-Fc fusion proteins comprising an amyloid-reactive peptide linked to a human Fc region. Also provided herein are methods of treating amyloid-based diseases and identifying amyloid deposits by administering an amyloid-reactive peptide-Fc fusion protein comprising an amyloid-reactive peptide linked to a human Fc region.Type: ApplicationFiled: May 4, 2022Publication date: July 4, 2024Applicants: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, Attralus, Inc.Inventors: Jonathan S. WALL, James S. FOSTER, Jaume PONS
-
RADIOLIGAND BINDING TO ANTI-DLL3 ANTIBODIES FOR PRETARGETED PET IMAGING AND THERAPEUTIC USES THEREOF
Publication number: 20240216557Abstract: The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.Type: ApplicationFiled: February 28, 2024Publication date: July 4, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases, Tri-Institutional Therapeutics Discovery Institute, Inc.Inventors: John T. POIRIER, Charles Rudin, Jason Lewis, Abdul Khan, David Andrew, Xinlei Chen, Ivo C. Lorenz, Kathryn M. Tully, Salomon Tendler -
Publication number: 20240216558Abstract: A light source for emitting emitted light having an SPD comprising: (a) a plurality of light emitters including at least one violet solid-state emitter, (b) at least one phosphor; wherein said light emitters and said at least one phosphor being configured such that: at least 25% of the power within the SPD is in the range 390-420 nm, and the emitted light has a chromaticity which is within a Duv distance of less than 5 points from the Planckian locus.Type: ApplicationFiled: August 7, 2023Publication date: July 4, 2024Inventors: AURELIEN J.F. DAVID, PHILIP BARTON, EMIL RADKOV
-
Publication number: 20240216559Abstract: An object of the present invention is to provide an ultraviolet light irradiation system and an ultraviolet light irradiation method having a P-MP configuration capable of obtaining a predetermined effect such as sterilization. An ultraviolet light irradiation system 301 according to the present invention includes an ultraviolet light source unit 11 that generates ultraviolet light, N (N is a natural number) irradiation units 13 that irradiate a desired site (irradiation target region ste) with the ultraviolet light, an optical switch 12 that switches the ultraviolet light to each of paths 14 to the irradiation units 13, and a switching control unit 15 that controls a switching operation of the optical switch 12 so as to give an opportunity to be supplied with an integrated light amount per unit time equal for each of the paths 14 on the basis of a transmission loss of the ultraviolet light for each of the paths 14 and an irradiation area where the irradiation unit 13 irradiates the ultraviolet light.Type: ApplicationFiled: June 4, 2021Publication date: July 4, 2024Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Tomohiro TANIGUCHI, Satoshi NARIKAWA, Ayako IWAKI, Takahito KIRIHARA, Kazuhide NAKAJIMA, Takashi MATSUI, Nobutomo HANZAWA, Yuto SAGAE, Chisato FUKAI
-
Publication number: 20240216560Abstract: A decontamination system for sterilizing a contaminated space, comprising at least one decontamination unit through which the air of the contaminated space is recirculated, which unit comprises an inlet arrangement for introducing air from the contaminated space into the unit, a discharge arrangement for discharging gas out of the unit, a fan for creating an air flow from the inlet arrangement to the discharging arrangement, H2O2 supply device for introducing H2O2 into the air flow inside the unit, where the decontamination unit comprises at least one of the discharge arrangement comprises detachable at least one outlet module through which the H2O2-air mixture is discharged out of the unit, or the inlet arrangement comprises at least one detachable inlet module for receiving air from a space into the unit.Type: ApplicationFiled: January 2, 2024Publication date: July 4, 2024Inventors: Kim Hagström, Ismo Grönvall, Harri Purho
-
Publication number: 20240216561Abstract: The invention provides a control device for controlling an ultraviolet light-based disinfection device arranged at a disinfection location, wherein the control device comprises: a user interface comprising a user interface element, wherein the user interface element is configured to control an operational parameter of the ultraviolet light-based disinfection device by providing a degree of control in controlling said operational parameter; a controller configured to: (i) determine a spatial relation of the control device relative to the ultraviolet light-based disinfection device and/or the disinfection location, and to (ii) change the degree of control of the user interface element in controlling said operational parameter based on said spatial relation.Type: ApplicationFiled: May 19, 2022Publication date: July 4, 2024Inventors: KARS-MICHIEL HUBERT LENSSEN, ERIK PETRUS JOHANNES MALLENS, TIES VAN BOMMEL, BARTEL MARINUS VAN DE SLUIS, DZMITRY VIKTOROVICH ALIAKSEYEU, TOBIAS BORRA
-
Publication number: 20240216562Abstract: A nasal swab kit for cleaning and sanitizing human nose nasal vestibules includes a pair of nasal swab devices, each of the devices having a body from which two spaced apart prongs extend, and each of the prongs having a free end to which a swab is attached. The swabs of a first of the devices are saturated with at least one cleaning ingredient selected from sterile water, glycerin, sodium chloride, sodium benzoate, PEG 60 hydrogenated castor oil, cocamidopropyl betaine and lavender oil. The swabs of a second of the devices are saturated with a sanitizing ingredient such as ethyl alcohol. The kit includes a first packet inside which the first device is sealed and a second packet inside which the second device is sealed wherein the packets are conjoined at a perforated seam.Type: ApplicationFiled: March 14, 2024Publication date: July 4, 2024Inventors: John W. Polley, Sean Yeom
-
Publication number: 20240216563Abstract: An ultraviolet (UV) light test device is suitable for ascertaining the efficacy of a germicidal UV light source. The UV light test device includes a population of viable microbial material having a residual water content of less than five percent. The population of viable microbial material is encapsulated in a container. At least a portion of the container is formed of a UV light transmissible material such that UV light from the germicidal UV light source is able to contact the population of viable microbial material.Type: ApplicationFiled: March 13, 2024Publication date: July 4, 2024Applicant: STRATIX LABS CORPORATIONInventors: Joshua Erickson, Mark Mulvahill
-
Publication number: 20240216564Abstract: Apparatus, methods and instructions for disinfecting air. The apparatus may include, and the methods may involve, a fixture. The fixture may include a germicidal light source. The fixture may include a fan. The fan may circulate air through a volume into which the germicidal light source propagates germicidal light. The light source may be configured to emit, upward from a horizontal plane, a beam that, absent reflection off an environmental object, does not cross the horizontal plane. The apparatus may include a shield that prevents light from the light source from crossing the horizontal plane. The sensor may face upward from the horizontal plane. The sensor may face downward from the horizontal plane.Type: ApplicationFiled: January 31, 2024Publication date: July 4, 2024Inventors: Shelley S. Wald, Voravit Puvanakijjakorn, Rong Feng Yu, David Xin Wang, Li Changyong, Zhou Tingting
-
Publication number: 20240216565Abstract: A decontamination unit for sterilizing a space, which unit has at least two air chambers, namely an outlet chamber and an inlet chamber; at least one inlet; and an outlet having discharge arrangement, a first plate between the outlet chamber and the inlet air chamber, wherein the first plate comprises an opening for discharging air from the inlet chamber into the outlet chamber, a fan, having a fan inlet and a fan outlet, arranged to the opening of the first plate for forming an air flow from the inlet to the outlet, a H2O2 supply device, wherein the H2O2 supply device is arranged next to the fan inlet or the fan outlet for introducing H2O2 directly into the air flow for forming H2O2-air mixture.Type: ApplicationFiled: January 2, 2024Publication date: July 4, 2024Inventors: Kim Hagström, Ismo Grönvall, Harri Purho
-
Publication number: 20240216566Abstract: An essential oil diffuser including multiple diffuser channels. Each diffuser channel includes an air pump and a cartridge assembly. The cartridge assemblies are removably receivable within a chassis assembly of the diffuser.Type: ApplicationFiled: March 18, 2024Publication date: July 4, 2024Inventor: Jake Dempsey
-
Publication number: 20240216567Abstract: A photocatalyst device reducing the separation distance between a light source and a catalyst part while securing visible light illumination over the entire range of the catalyst part, reducing the package size, and increasing the amount of visible light irradiated to the catalyst part to enhance its photocatalytic reactivity. The photocatalyst device, generating a photocatalytic reaction and emitting superoxide radicals into internal flow path of air conditioning case to purify air blown into a vehicle passenger room along the internal flow path, includes a photocatalyst body with a light source part and a catalyst part installed on it, where catalyst part causes a photocatalytic reaction by light emitted from the light source part, and a light processing part processing the light emitted from the light source part so as to increase an irradiance rate of the light of the light source part with respect to the catalyst part.Type: ApplicationFiled: June 8, 2022Publication date: July 4, 2024Inventors: Chang Hyun BAEK, Young Chul KIM, Sang Ho OH, Chae Geun LIM, Yun Sung JO
-
Publication number: 20240216568Abstract: A bulb lamp, including a lamp shell, a light-transmitting cover, a power panel, a lamp panel, at least one illumination module and at least one sterilization module. An annular first step extends inside the peripheral side of the lamp shell, and a plurality of air inlets are provided above the first step; the light-transmitting cover is connected to the bottom ring side of the lamp shell and surrounds the lamp shell to form an accommodating cavity, the bottom of the light-transmitting cover is provided with at least one air outlet in communication with the accommodating cavity, and the accommodating cavity is in communication with the air inlet; the power panel is arranged in the accommodating cavity; the lamp panel is arranged in the accommodating cavity and is lower than the first step, and an installation space is formed between the lamp panel and the first step.Type: ApplicationFiled: April 4, 2023Publication date: July 4, 2024Applicant: Shenzhen Guanke Technologies Co., LtdInventors: Qing Lan, Ligen Liu, Liang Wu, Xuren Qiu, Qinwan Gong
-
Publication number: 20240216569Abstract: A light module includes a support including a first region and a second region, a light source disposed on the support, and a reflector disposed on the support and covering at least a side of the light source. The reflector includes a first reflector disposed on the first region and a second reflector disposed on the second region. The first reflector includes a first slope extending along a longitudinal direction of the first region, and the second reflector includes a second slope extending along a longitudinal direction the second region. The second slope has a width that is longer than a width of the first slope.Type: ApplicationFiled: March 18, 2024Publication date: July 4, 2024Applicant: SEOUL VIOSYS CO., LTD.Inventors: Eun Ju KIM, Chung Hoon LEE, Jae Young CHOI
-
Publication number: 20240216570Abstract: An air purification module for purifying air includes a photocatalyst filter and a light source unit sequentially arranged in a selected direction. The light source unit is spaced apart from the photocatalyst filter to provide light to the photocatalyst filter and includes a substrate and a light source disposed on the substrate. The substrate includes at least one aperture to control a flow channel and a flow velocity of air so as to improve air purification effects through the photocatalyst filter when the air flows from the substrate towards the photocatalyst filter.Type: ApplicationFiled: March 15, 2024Publication date: July 4, 2024Applicant: SEOUL VIOSYS CO., LTD.Inventors: Jae Hak JEONG, Ji Won KIM, Sang Cheol SHIN
-
Publication number: 20240216571Abstract: The present chitosan-based superfine fiber invention relates to compositions, formulations, and processes that result in numerous significant advantages for the production and use of superfine fiber bioactive matrices in biomedical applications. The present invention relates to superfine, chitosan-based fibers, wherein the chitosan-based fibers have a percentage chitosan content of at least about 20% w/w, and highly conformable and compliant matrices comprising such fibers, processes for their production, and related formulations. The superfine chitosan-based fibers of the invention preferably include microfibers with diameter less than or equal to about 10 microns and micron and submicron fibers that are about 2 microns and less.Type: ApplicationFiled: January 17, 2024Publication date: July 4, 2024Inventors: Brian Clare, Radim Dvorák, Simon McCarthy, Jirí Machát
-
Publication number: 20240216572Abstract: The present invention relates to sterile and desiccated biomaterials comprising devitalized differentiated cells having tissue regenerating and/or repairing properties, and a particulate material, the cells and the particulate material being embedded in an extracellular matrix. The particulate material is preferably gelatin, a ceramic material, or a demineralized bone matrix (DBM).Type: ApplicationFiled: November 27, 2020Publication date: July 4, 2024Applicant: Novadip BiosciencesInventors: DENIS DUFRANE, Nicolas THEYS